Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy

le Durrant, L G, Noble, P, Spendlove, I
Foilsithe 2012

CD55 is over-expressed in the tumour environment

le Li, L, Spendlove, I, Morgan, J, Durrant, L G
Foilsithe 2001

Characterization of a human X mouse T cell hybridoma and identification of a clone secreting and binding interleukin-2.

le Durrant, L G, Parkar, M, Kenworthy, N, Taylor, G M
Foilsithe 1984

Co-stimulation of gastrointestinal tumour cell growth by gastrin, transforming growth factor alpha and insulin like growth factor-I.

le Durrant, L. G., Watson, S. A., Hall, A., Morris, D. L.
Foilsithe 1991

Hormonal control of gastric and colorectal cancer in man.

le Morris, D L, Watson, S A, Durrant, L G, Harrison, J D
Foilsithe 1989

Development of an ELISA to detect early local relapse of colorectal cancer.

le Durrant, L. G., Jones, H., Armitage, N. C., Baldwin, R. W.
Foilsithe 1989

Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy

le Shehata, M, Mukherjee, A, Deen, S, Al-Attar, A, Durrant, L G, Chan, S
Foilsithe 2009

Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36.

le Austin, E B, Robins, R A, Durrant, L G, Price, M R, Baldwin, R W
Foilsithe 1989

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer

le Popple, A, Durrant, L G, Spendlove, I, Rolland, P, Scott, I V, Deen, S, Ramage, J M
Foilsithe 2012

Enhanced recognition of human colorectal tumour cells using combinations of monoclonal antibodies.

le Durrant, L. G., Robins, R. A., Ballantyne, K. C., Marksman, R. A., Hardcastle, J. D., Baldwin, R. W.
Foilsithe 1989

Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression.

le Durrant, L. G., Ballantyne, K. C., Armitage, N. C., Robins, R. A., Marksman, R., Hardcastle, J. D., Baldwin, R. W.
Foilsithe 1987

Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.

le Durrant, L G, Byers, V S, Scannon, P J, Rodvien, R, Grant, K, Robins, R A, Marksman, R A, Baldwin, R W
Foilsithe 1989

Antigenicity of newly established colorectal carcinoma cell lines.

le Durrant, L. G., Robins, R. A., Pimm, M. V., Perkins, A. C., Armitage, N. C., Hardcastle, J. D., Baldwin, R. W.
Foilsithe 1986

Sensitivity of newly established colorectal cell lines to cytotoxic drugs and monoclonal antibody drug conjugates.

le Durrant, L. G., Garnett, M. C., Gallego, J., Armitage, N. C., Ballantyne, K. C., Marksman, R. A., Hardcastle, J. D., Baldwin, R. W.
Foilsithe 1987

Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma

le Pritchard-Jones, K, Spendlove, I, Wilton, C, Whelan, J, Weeden, S, Lewis, I, Hale, J, Douglas, C, Pagonis, C, Campbell, B, Alvarez, P, Halbert, G, Durrant, L G
Foilsithe 2005

Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer

le Maxwell-Armstrong, C A, Durrant, L G, Buckley, T J D, Scholefield, J H, Robins, R A, Fielding, K, Monson, J R T, Guillou, P, Calvert, H, Carmichael, J, Hardcastle, J D
Foilsithe 2001

Native/citrullinated LL37-specific T-cells help autoantibody production in Systemic Lupus Erythematosus

le Lande, R., Palazzo, R., Gestermann, N., Jandus, C., Falchi, M., Spadaro, F., Riccieri, V., James, E. A., Butera, A., Boirivant, M., Feldmeyer, L., Surbeck, I., Di Lucca, J., Stuber, F., Spinelli, F. R., Botti, E., Marinari, B., Bianchi, L., Pica, R., Cerbelli, B., Giannakakis, K., Auteri, S. E., Daniels, I., Durrant, L. G., Horstman, S., Costanzo, A., Romero, P., Alessandri, C., Conti, F., Valesini, G., Gilliet, M., Chizzolini, C., Frasca, L.
Foilsithe in Sci Rep (2020)